The rationale to target CD133 was an acquisition of a CD19-negative myeloid phenotype, allowing for the immune escape of MLL-r B-ALL from CD19 CAR T-cell therapy in some patients [276,277]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.